학술논문
Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome
Document Type
article
Author
Raúl Martínez-Castillo; Carmen González-Gallardo; José I. Muñoz-Ávila; Pilar Font; Marta Villalba-González; Indira Stoikow; Ignacio Fernández-Choquet de Isla; Francisco Pugliese; Roberto Anaya-Alaminos; José L. García-Serrano; Francisco Hermoso-Fernández; Fabio Contieri; José E. Muñoz-de-Escalona-Rojas; Lorena Pérez-Fajardo; Mario Blanco-Blanco; Yolanda Jiménez-Gómez; Miguel González-Andrades
Source
Biomedicine & Pharmacotherapy, Vol 160, Iss , Pp 114368- (2023)
Subject
Language
English
ISSN
0753-3322
Abstract
Purpose: To evaluate long-term visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients treated with anti-vascular endothelial growth factor (VEGF) agents depending on the time delay from confirmed diagnosis to treatment initiation. Materials and methods: Seventy-three nAMD patients (73 eyes) treated with anti-VEGF agents for 12 months using the pro re nata regimen were included in this retrospective longitudinal study. Patients were split into 3 groups according to the time from diagnosis to first anti-VEGF injection: 7 days (group 3). Decimal best-corrected visual acuity (VA) and macular thickness (MT) were recorded at baseline and 1–2-, 3–4-, 6- and 12-month later. Furthermore, age, gender as well as the applied treatment and number of injections after 12 months of treatment were also registered and compared. Results: Long-term effect of the treatment demonstrated enhanced VA in group 1 patients compared with the rest of groups after 1–2-, 6-, and 12-month follow-up (P